Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Inclusion (key) * Confirmed generalized MG: Diagnosis ≥6 months before screening, anti-AChR antibody positive, and supportive diagnostic evidence (e.g., abnormal SFEMG/RNS or response to anticholinesterase therapy). * Disease severity: MGFA Class II-IV at screening. * Symptoms threshold: MG-ADL ≥6 at screening and on Day 1. * Meningococcal vaccination: Up to date within 3 years or vaccinated before first dose to mitigate risk with complement inhibition. * Body weight: ≥40 kg. * Vaccinated against meningococcal infections within the 3 years prior to, or at the time of, initiating study drug. Exclusion (key) * Thymic disease: * Untreated thymic malignancy/carcinoma/thymoma excluded. * Prior thymic malignancy allowed only if treatment completed \>5 years, no recurrence in last 5 years, and clear CT/MRI within 6 months. * Prior benign thymoma allowed if confirmed benign, treatment \>12 months ago, no recurrence in last 12 months, and clear CT/MRI within 6 months; otherwise follow malignancy rules. * Thymectomy within the last 12 months * Infection risk: * History of meningococcal disease or unresolved infection, or active systemic infection within 14 days of Day 1 excluded. * Persistent/recurrent infections in past 12 months that add risk * HIV, active HBV (HBsAg+ or anti-HBc+ with anti-HBs-), or active HCV (unless documented successful treatment/SVR) * Safety/medical status: * Hypersensitivity to study drug components (including murine proteins) * Recent …